Value20202021202220232024TTMSelling/general/admin expenses747 M818 M828 M926 M1.1 B—Research & development226 M230 M236 M274 M320 M—Operating income332 M389 M695 M813 M842 M—Non-Operating Income, Total——————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income361 M426 M734 M862 M900 M—Equity in earnings——————Taxes125 M115 M186 M194 M229 M—Non-controlling/minority interest————8 M—After tax other income/expense——————Net income before discontinued operations236 M311 M548 M668 M671 M—Discontinued operations——————Net income236 M311 M548 M668 M671 M—Dilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders——————Basic earnings per share (Basic EPS)——————Diluted earnings per share (Diluted EPS)——————Average basic shares outstanding——————Diluted shares outstanding——————EBITDA——————EBIT332 M389 M696 M813 M842 M—Cost of revenue1.19 B1.32 B1.3 B1.39 B1.58 B—Other cost of goods sold——————Depreciation & amortization (cash flow)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.